SMALL_CELL_LUNG_CANCER US . HENGENIX BIOTECH, Una Filial de SHANGHÁI HENLIUS BIOTECH , Utilizará la Plataforma PROPHET de ONCOHOST Para Identificar BIOMARCADORES en un Ensayo de Fase III Que Prueba el Anticuerpo Anti-PD-1 de Henlius, SERPLULIMAB Más QUIMIOTERAPIA en Pacientes con Cáncer de Pulmón de Células Pequeñas en Estadio Extenso .

  

SERPLULIMAB ESTA EN ENSAYOS CLÍNICOS DE FASE III EN INTENTO DE PODER SER UNO DE LOS TRATAMIENTOS STANDARD DE PRIMERA LINEA PARA SMALL-CELL LUNG CÁNCER A NIVEL MUNDIAL Y DESBANCAR A LOS TRATAMIENTOS ACTUALES  .

OncoHost, Hengenix Biotech Exploring Lung Cancer Resistance Biomarkers in Immunotherapy Trial .

Oct 03, 2023 | staff reporter .

NEW YORK – Hengenix Biotech, an affiliate of Shanghai Henlius Biotech, will use OncoHost's Prophet platform to identify Biomarkers in a Phase III trial testing Henlius' anti-PD-1 Antibody SERPLULIMAB plus CHEMOTHERAPY in Patients with EXTENSIVE-STAGE SMALL CELL LUNG CÁNCER (ES-SCLC) .

OncoHost on Tuesday said that in the Phase III Trial researchers will compare the activity of SERPLULIMAB plus CHEMOTHERAPY against Roche's anti-PD-1 Antibody TECENTRIQ (atezolizumab) plus CHEMOTHERAPY in previously untreated ES-SCLC patients . They will use the Prophet platform to look for proteomic biomarkers that characterize resistance patterns in patients with the goal of identifying those most likely to benefit from the SERPLULIMAB - Chemotherapy Combination . ...

High Dose Hyperfractionated Thoracic Radiotherapy vs. Standard Dose for Limited Stage Small-Cell Lung Cancer: A Multicenter, Open-Label Randomized, Phase III Trial .

 

Results :

Between June 30, 2017, and April 6, 2021, 224 eligible patients were enrolled and randomly assigned to 54 Gy (n = 108) or 45 Gy (n = 116). Median follow-up for the primary analysis was 45 months (IQR 41-48). Median overall survival was significantly improved in the 54 Gy group (62.4 months) compared with the 45 Gy group (43.1 months; p = 0.001). Median progression-free survival was significantly improved in the 54 Gy group (30.5 months) compared with the 45 Gy group (16.7 months; p = 0.044). The most common grade 3-4 adverse events were neutropenia (30 [28%] of 108 patients in the 54 Gy group vs 27 [23%] of 116 patients in the 45 Gy group), neutropenic infections (6 [6%] vs 2 [2%]), thrombocytopenia (13 [12%] vs 12 [10%]), anemia (6 [6%] vs 4 [3%]), and esophagitis (1 [1%] vs 3 [3%]). Treatment-related serious adverse events occurred in 9 [8%] patients in the 54 Gy group and 16 [14%] patients in the 45 Gy group. There were one treatment-related deaths in 54 Gy group (myocardial infarction).

Conclusion :

Compared with standard thoracic radiotherapy dose of 45 Gy, the high dose of 54 Gy improved overall survival and progression-free survival without increasing toxicities in patients with LS-SCLC, supporting twice-daily hyperfractionated thoracic radiotherapy of 54 Gy with concurrent chemotherapy is an alternative treatment option for LS-SCLC. This study is complete and registered with ClinicalTrials.gov, NCT03214003 . ...